Emixustat

Drug Profile

Emixustat

Alternative Names: ACU-02; ACU-4429; ACU-4429 HCl; Emixustat HCl; Emixustat hydrochloride

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acucela
  • Developer Acucela; Otsuka Pharmaceutical
  • Class Cyclohexanes; Eye disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Retinoid isomerohydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Dry age-related macular degeneration
  • Phase II Diabetic retinopathy; Stargardt disease

Most Recent Events

  • 28 Jun 2018 9243873- updated intro, orgT, TT and HE. Brief profile review done
  • 21 Jun 2018 Emixustat is available for licensing as of 28 Jun 2018
  • 21 Jun 2018 Efficacy data from a phase II trial in Diabetic retinopathy released by Acucela
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top